Celldex Therapeutics CLDX Business Segments — Product Development Expense

Similar metrics at other companies

QURESingle Reportable — Laboratory And Development Expense

$14.76M-7.6%

IOVASingle Reportable — Research And Development Expense

$57.37M-13.1%

CAPRSingle Reportable — Research And Development Expense

$27.38M+44.7%

OCULSingle Reportable — Research And Development Expense Other Clinical And Preclinical Programs

$758K-14.7%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

MMSISingle Reportable — Research And Development Expense

$22.61M+0.6%

Questions, answered.

What is Celldex Therapeutics's business segments — product development expense?

Celldex Therapeutics (CLDX) reported business segments — product development expense of $50.16M in Q1 2026.

How has Celldex Therapeutics's business segments — product development expense changed year-over-year?

Celldex Therapeutics's business segments — product development expense increased by 55.9% year-over-year, from $32.17M to $50.16M.

What does business segments — product development expense mean?

This metric measures the specific costs directly attributable to the clinical development and advancement of the company's therapeutic candidates. It focuses on the capital allocated to moving pipeline products through various phases of clinical trials and regulatory approval processes. This is a key indicator of the company's progress toward commercializing its drug portfolio.